Loading...
XLON
OPTI
Market cap16mUSD
Jul 15, Last price  
12.00GBP
1D
5.45%
1Q
-33.33%
Jan 2017
-80.33%
IPO
-99.61%
Name

OptiBiotix Health PLC

Chart & Performance

D1W1MN
No data to show
P/E
P/S
1,924.84
EPS
Div Yield, %
Shrs. gr., 5y
1.86%
Rev. gr., 5y
4.60%
Revenues
644k
+40.92%
000161,5970028,200288,119191,073514,289744,8831,523,2472,212,932457,000644,000
Net income
-2m
L
-32,000-16,000-36,000-1,652,815-1,632,056-810,706-1,280,629-1,297,8711,907,441-1,919,276-2,368,3625,801,8676,261,0002,587,000-2,039,000
CFO
-2m
L+37.69%
-27,000-65,000-42,000-1,076,200-376,789-706,243-983,464-1,246,066-1,753,241-1,233,548-1,723,248-927,963-1,564,661-1,109,000-1,527,000
Earnings
Sep 25, 2025

Profile

OptiBiotix Health Plc, a life sciences company, engages in the research and development of microbiome modulators primarily in the United Kingdom. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that impacts human physiology deriving potential health benefits. Its products include Slimbiome, a natural ingredient, which offers a healthy and hunger-free weight management system; SlimBiome Medical, a natural supplement for weight management; CholBiome, a food supplement for maintaining healthy levels of cholesterol; Lactobacillus plantarum LPLDL, a probiotic that aids elements of cardiovascular and wellbeing; LPGOS, a galactooligosaccharid that is used in food products and applications, which helps in reducing cardiovascular risk factors and enhancing health; WellBiome, a functional fibre and mineral blend that supports health & wellbeing by promoting the diversity of the gut microbiome; and Sweetbiotix, a sweetener for use in food and beverages. The company's products prevents and manages chronic lifestyle diseases, including obesity, hypercholesterolemia and lipid profiles, and diabetes. OptiBiotix Health Plc was founded in 2012 and is headquartered in York, the United Kingdom.
IPO date
Sep 09, 2011
Employees
9
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑112017‑112016‑112015‑11
Income
Revenues
644
40.92%
457
-79.35%
Cost of revenue
1,513
1,275
Unusual Expense (Income)
NOPBT
(869)
(818)
NOPBT Margin
Operating Taxes
(4)
(146)
Tax Rate
NOPAT
(865)
(672)
Net income
(2,039)
-178.82%
2,587
-58.68%
Dividends
Dividend yield
Proceeds from repurchase of equity
485
BB yield
-3.93%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(7,328)
(9,203)
Cash flow
Cash from operating activities
(1,527)
(1,109)
CAPEX
(168)
Cash from investing activities
1,110
(331)
Cash from financing activities
485
FCF
(655)
127
Balance
Cash
635
1,052
Long term investments
6,693
8,151
Excess cash
7,296
9,180
Stockholders' equity
3,642
6,447
Invested Capital
5,230
4,458
ROIC
ROCE
EV
Common stock shares outstanding
90,191
93,213
Price
0.27
101.89%
0.13
-71.20%
Market cap
24,126
95.34%
12,351
-71.90%
EV
16,798
3,148
EBITDA
(664)
(594)
EV/EBITDA
Interest
5,013
Interest/NOPBT